Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

Endocrine. 2016 May;52(2):214-21. doi: 10.1007/s12020-015-0830-4. Epub 2015 Dec 21.

Abstract

Efficient treatment of radio refractory thyroid cancer is still a major challenge. The recent identification of genetic and epigenetic alterations present in almost all differentiated tumors has revealed novel molecular targets, which can hopefully be exploited to create new treatments for these tumors. This review looks briefly at some of the innovative strategies currently being investigated for the treatment the radioiodine-resistant thyroid cancers.

Keywords: Differentiated thyroid cancer; Molecular targets; Nanodevices; Radioiodine; Re-differentiation strategies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinogenesis / drug effects
  • Drug Delivery Systems
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Molecular Targeted Therapy*
  • Nanostructures / chemistry
  • Receptors, Thyrotropin / agonists
  • Thyroid Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Iodine Radioisotopes
  • Receptors, Thyrotropin